Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer

SpringerPlus

Volumn 3, Issue 1, 2014, Pages 1-9

  Hurvitz, Sara A ^a   Bosserman, Linda D ^b   Chan, David ^c   Hagenstad, Christopher T ^d   Kass, Frederick C ^e   Smith, Frederick P ^f   Rodriguez, Gladys I ^g   Childs, Barrett H ^h   Slamon, Dennis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Wilshire Oncology Medical Group Inc ^*  (United States)

^c Torrance Memorial Hospital   (United States)

^d Suburban Hematology/Oncology   (United States)

^e Cancer Center of Santa Barbara   (United States)

^f GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g TEXAS ONCOLOGY   (United States)

^h SANOFI   (France)

Author keywords

Adverse events; Anthracyclines; Antiangiogenic; Congestive heart failure; Trastuzumab

Indexed keywords

EID: 84903994735     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-244     Document Type: Article

References (24)

1. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS: RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011, 29(32): 4286-4293.
2. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA: Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011, 29(6): 632-638.
3. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21(8): 1431-1439.
4. Davidson NE, Gelmann EP, Lippman ME, Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1987, 1(3): 216-223.
5. Epstein M, Ayala R, Tchekmedyian N, Borgstrom P, Pegram DJ, Slamon DJ: HER-2/neu-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 2002, 76(suppl. 1): S143.
6. Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V: AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013, 31(14): 1719-1725.
7. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L: Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21(6): 976-983.
8. Hurvitz SA, Pegram M, Lin LS: Final results of a phase 2 trial evaluating trastuzumab and bevacizumab as first-line treatment of HER2-amplified advanced breast cancer. 2009. Proc SABCS, Abs 6094.
9. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD: Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004, 10(5): 1706-1716.
10. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C: Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013, 14(1): 72-80.
11. Martin DE, Hall MN: The expanding TOR signaling network. Curr Opin Cell Biol 2005, 17(2): 158-166.
12. Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E: Doxorubicin in combination with fluorouracil and cyclophosphamide (i. v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i. v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 2003, 14(6): 833-842.
13. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26): 2666-2676.
14. National Cancer Institute: Phase III randomized study of adjuvant therapy comprising doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with versus without bevacizumab in patients with lymph node-positive or high-risk, lymph node-negative breast cancer. Available at: http://clinicaltrials. gov/ct/show/NCT0043351 Accessed 5/5/2014 Available at: Accessed 5/5/2014.
15. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004, 96(10): 739-749.
16. Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, Ciruelos E, von Moos R, Chang HT, Duenne AA, Miles DW: Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer 2011, 47(16): 2387-2395. doi: 10. 1016/j. ejca. 2011. 06. 018. Epub 2011 Jul 15. PMID: 21757334.
17. Robert NJ, Diéras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, Perez E, Yardley D, Zhou X, Phan S: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009, 27(15s): suppl; abstr 1005.
18. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16): 1673-1684.
19. Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1): 9-29.
20. Slamon DJ, Swain SM, Buyse M, Martin M, Geyer CE, Im Y-H, Pienkowski T, Kim S-B, Robert NJ, Steger G, Crown J, Verma S, Eiermann W, Costantino JP, Im S-A, Mamounas EP, Schwartzberg L, Paterson A, Mackey JR, Provencher L, Press MF, Thirlwell M, Bee-Munteanu V, Henschel V, Crepelle-Flechais A, Wolmark N: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. 2013. San Antonio Breast Cancer Symposium, Abstract S1-03.
21. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365(14): 1273-1283.
22. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001, 61(8): 3369-3372.
23. United States Food and Drug Administration: FDA Commissioner announces Avastin decision. 2011.
24. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA: Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000, 19(31): 3460-3469.